Authors
- Eleonora Proia*
- Alessio Ragno*
- Lorenzo Antonini*
- Manuela Sabatino*
- Milan Mladenovič*
- Roberto Capobianco
- Rino Ragno*
* External authors
Venue
- Journal of Computer-Aided Molecular Design
Date
- 2022
Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal
Eleonora Proia*
Alessio Ragno*
Lorenzo Antonini*
Manuela Sabatino*
Milan Mladenovič*
Rino Ragno*
* External authors
Journal of Computer-Aided Molecular Design
2022
Abstract
The main protease (Mpro) of SARS-Cov-2 is the essential enzyme for maturation of functional proteins implicated in viral replication and transcription. The peculiarity of its specific cleavage site joint with its high degree of conservation among all coronaviruses promote it as an attractive target to develop broad-spectrum inhibitors, with high selectivity and tolerable safety profile. Herein is reported a combination of three-dimensional quantitative structure–activity relationships (3-D QSAR) and comparative molecular binding energy (COMBINE) analysis to build robust and predictive ligand-based and structure-based statistical models, respectively. Models were trained on experimental binding poses of co-crystallized Mpro-inhibitors and validated on available literature data. By means of deep optimization both models’ goodness and robustness reached final statistical values of r2/q2 values of 0.97/0.79 and 0.93/0.79 for the 3-D QSAR and COMBINE approaches respectively, and an overall predictiveness values of 0.68 and 0.57 for the SDEPPRED and AAEP metrics after application to a test set of 60 compounds covered by the training set applicability domain. Despite the different nature (ligand-based and structure-based) of the employed methods, their outcome fully converged. Furthermore, joint ligand- and structure-based structure–activity relationships were found in good agreement with nirmatrelvir chemical features properties, a novel oral Mpro-inhibitor that has recently received U.S. FDA emergency use authorization (EUA) for the oral treatment of mild-to-moderate COVID-19 infected patients. The obtained results will guide future rational design and/or virtual screening campaigns with the aim of discovering new potential anti-coronavirus lead candidates, minimizing both time and financial resources. Moreover, as most of calculation were performed through the well-established web portal 3d-qsar.com the results confirm the portal as a useful tool for drug design.
Related Publications
Providing neural networks with the ability to learn new tasks sequentially represents one of the main challenges in artificial intelligence. Unlike humans, neural networks are prone to losing previously acquired knowledge upon learning new information, a phenomenon known as …
Graph Neural Networks (GNNs) have proven their effectiveness in various graph-structured data applications. However, one of the significant challenges in the realm of GNNs is representation learning, a critical concept that bridges graph pooling, aimed at creating compressed…
Contextual integration is fundamental to human language comprehension. Language models are a powerful tool for studying how contextual information influences brain activity. In this work, we analyze the brain alignment of three types of language models, which vary in how the…
JOIN US
Shape the Future of AI with Sony AI
We want to hear from those of you who have a strong desire
to shape the future of AI.



